MYC and adenocarcinoma: A significant impairment of mPIN and adenocarcinoma development was observed in Hi-Myc:ArL/Y:Gli1CreER/+ mice in comparison with Hi-Myc:Gli1CreER/+ controls when they both received TM at postnatal day 14, P14 (Fig. 2b).